FLT3 and acute myeloid leukemia: Moreover, AZD5991 and gilteritinib or MRX-2843 cooperated in the suppression of the FLT3-mutated AML progenitor cells but spared normal hematopoietic progenitor cells, indicating a therapeutic window for these promising combination therapies.